Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
PHAT Phathom Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: PHAT
Price (delayed)
$4.33
Market cap
$302.3M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.19
Enterprise value
$634.49M
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States,
Highlights
Phathom Pharmaceuticals's gross profit has increased by 49% from the previous quarter
The revenue is up by 48% from the previous quarter
The equity has shrunk by 128% YoY and by 33% QoQ
The quick ratio has dropped by 55% year-on-year and by 14% since the previous quarter
Key stats
What are the main financial stats of PHAT
Market
Valuations
Earnings
Shares outstanding
69.81M
Market cap
$302.3M
Enterprise value
$634.49M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
3.81
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.75
Revenue
$81.86M
Gross profit
$70.59M
Operating income
-$286.38M
Net income
-$345.79M
EBIT
-$272.88M
EBITDA
-$272.12M
Free cash flow
-$282.79M
Per share
Balance sheet
Liquidity
EPS
-$5.19
EPS diluted
-$5.19
Free cash flow per share
-$3.93
Book value per share
-$4.86
Revenue per share
$1.14
TBVPS
$4.09
Total assets
$294.21M
Total liabilities
$632.58M
Debt
$547.37M
Equity
-$338.38M
Working capital
$190.87M
Debt to equity
-1.62
Current ratio
3.58
Quick ratio
3.4
Net debt/EBITDA
-1.22
Margins
Efficiency
Dividend
EBITDA margin
-332.4%
Gross margin
86.2%
Net margin
-422.4%
Operating margin
-349.8%
Return on assets
-100.3%
Return on equity
N/A
Return on invested capital
-53.2%
Return on capital employed
-123.9%
Return on sales
-333.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PHAT stock price
How has the Phathom Pharmaceuticals stock price performed over time
Intraday
-1.37%
1 week
30.82%
1 month
7.44%
1 year
-60.24%
YTD
-46.67%
QTD
-30.94%
Financial performance
How have Phathom Pharmaceuticals's revenue and profit performed over time
Revenue
$81.86M
Gross profit
$70.59M
Operating income
-$286.38M
Net income
-$345.79M
Gross margin
86.2%
Net margin
-422.4%
The operating margin has soared by 96% year-on-year and by 30% since the previous quarter
PHAT's net margin has surged by 96% year-on-year and by 30% since the previous quarter
Phathom Pharmaceuticals's gross profit has increased by 49% from the previous quarter
The revenue is up by 48% from the previous quarter
Price vs fundamentals
How does PHAT's price correlate with its fundamentals
Growth
What is Phathom Pharmaceuticals's growth rate over time
Valuation
What is Phathom Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
3.81
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.75
The EPS has declined by 16% year-on-year
The equity has shrunk by 128% YoY and by 33% QoQ
The price to sales (P/S) is 87% lower than the last 4 quarters average of 30.0
The revenue is up by 48% from the previous quarter
Efficiency
How efficient is Phathom Pharmaceuticals business performance
The ROS has soared by 96% year-on-year and by 30% since the previous quarter
Phathom Pharmaceuticals's ROA has decreased by 29% YoY and by 8% from the previous quarter
The ROIC has grown by 12% YoY
Dividends
What is PHAT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PHAT.
Financial health
How did Phathom Pharmaceuticals financials performed over time
The total assets is 53% smaller than the total liabilities
The quick ratio has dropped by 55% year-on-year and by 14% since the previous quarter
The current ratio has plunged by 54% YoY and by 15% from the previous quarter
The equity has shrunk by 128% YoY and by 33% QoQ
The debt to equity has grown by 47% year-on-year and by 23% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.